Skip to main content

Gsk Plc ADR(GSK-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low55.78
Day High56.34
Open:56.29
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Tipranks
GlaxoSmithKline (GSK) Gets a Sell from J.P. Morgan
Motley Fool
Nvidia Rival Cerebras Files for an IPO: What Investors Should Know
Tipranks
GSK’s New Pneumonia Vaccine Trial Targets a Growing Adult Market
Tipranks
GlaxoSmithKline (GSK) Gets a Hold from Deutsche Bank
Tipranks
Barclays Reaffirms Their Sell Rating on GlaxoSmithKline (GSK)
Tipranks
GlaxoSmithKline (GSK) Gets a Hold from Citi
Tipranks
GlaxoSmithKline (GSK) Receives a Buy from Jefferies
Tipranks
J.P. Morgan Keeps Their Sell Rating on GlaxoSmithKline (GSK)
Tipranks
Goldman Sachs Sticks to Their Hold Rating for GlaxoSmithKline (GSK)
Tipranks
UBS Remains a Hold on GlaxoSmithKline (GSK)
MarketBeat
3 Bargain-Cheap Small Caps Worth a Second Look
MarketBeat.com
Tipranks
Barclays Sticks to Its Sell Rating for GlaxoSmithKline (GSK)
Tipranks
J.P. Morgan Keeps Their Sell Rating on GlaxoSmithKline (GSK)
Tipranks
GSK’s New Cancer Drug GSK5533524 Enters First‑in‑Human Testing: What Investors Should Watch
Tipranks
Jefferies Reaffirms Their Buy Rating on GlaxoSmithKline (GSK)
Tipranks
Barclays Sticks to Its Sell Rating for GlaxoSmithKline (GSK)
Tipranks
J.P. Morgan Sticks to Its Sell Rating for GlaxoSmithKline (GSK)
Tipranks
GSK’s New Efimosfermin Alfa Trial Signals Renewed Push Into Fatty Liver Disease
Tipranks
Berenberg Bank Keeps Their Hold Rating on GlaxoSmithKline (GSK)
Tipranks
GlaxoSmithKline (GSK) Gets a Sell from J.P. Morgan
Tipranks
Berenberg Bank Remains a Hold on GlaxoSmithKline (GSK)
Tipranks
GlaxoSmithKline (GSK) Gets a Buy from Shore Capital
Tipranks
GlaxoSmithKline (GSK) Gets a Hold from Deutsche Bank
Tipranks
GlaxoSmithKline (GSK) Receives a Buy from Bernstein
Tipranks
GSK Advances New Phase 3 Trial in Hard-to-Treat Ovarian Cancer: What Investors Should Watch
Tipranks
GSK Wins First U.S. Approval for Lynavoy in PBC-Related Itch, Advancing Hepatology Push
Tipranks
GSK Discloses Chief People Officer’s March 16 ADS Purchase Under Pension Plan
Tipranks
GSK Expands March Buyback With 732,112-Share Repurchase
Tipranks
GlaxoSmithKline (GSK) Receives a Sell from Barclays
Tipranks
GSK Discloses Notional ADS Acquisition by US President Under Executive Savings Plan
Tipranks
GSK Boosts Treasury Stock With Latest Share Buyback on 16 March 2026
Motley Fool
This Biotech Stock Surged 75% Last Quarter and Pulled a New $9 Million Investment

Profile

GSK plc is a biopharma company. Its vaccine portfolio protects people from meningitis, shingles, flu, polio, measles and many more. GSK plc, formerly known as GLAXOSMITHKLINE, is based in Brentford, the United Kingdom.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.